Alpha-synuclein levels in multiple sclerosis patients with restless leg syndrome
Abstract
Purpose: The restless legs syndrome is more frequent and critical in Multiple Sclerosis patients, and it harms their general well-being and life quality. Alpha-synuclein is a synuclein protein that can have an impact on the pathway of signaling, affecting the Dopamin 2 receptor and its receptor trafficking. Studies have shown that the decrease in dopamine 2 receptor and Restless Legs Syndrome disease are correlated. This study is aimed to ascertain the alpha-synuclein level in multiple sclerosis patients with restless legs syndrome.
Materials and Methods: We took blood samples from 40 multiple sclerosis patients and 20 healthy individuals. Half of the patient group had Multiple Sclerosis with restless leg syndrome. In the study groups, the alpha-synuclein level was determined by quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme-dependent immunosorbent assay (ELISA).
Results: Alpha-synuclein gene expression level was found or be significantly lower in restless leg syndrome patients with multiple sclerosis than the Alpha-synuclein gene expression level in the control group.
Conclusion: Alpha-synuclein may have an impact on the pathogenesis of the restless leg syndrome of multiple sclerosis disease. Further investigations are required to determine the impact of alpha-synuclein in the pathogenesis of restless leg syndrome in multiple sclerosis disease.
Keywords
Restless leg syndrome,multiple sclerosis,alpha-synuclein,RT-PCR
Kaynakça
- Carnero Contentti E, Lopez PA, Nadur D, Balbuena ME, Finkelstein AM, Tkachuk V. Impact, Frequency, and Severity of Restless Legs Syndrome in Patients with Multiple Sclerosis in Argentina. International journal of MS care. 2019;21(4):157-165.
- Kurt S. The Comorbidity of Migraine and Restless Legs Syndrome. Current neurology and neuroscience reports. 2019;19(9):60.
- Romigi A, Vitrani G, Caccamo M, Centonze D. Restless Legs Syndrome Related to Vortioxetine: A Case Report. Journal of clinical psychopharmacology. 2019;39(5):514-516.
- Kidd PM. Multiple sclerosis, an autoimmune inflammatory disease: prospects for its integrative management. Alternative medicine review : a journal of clinical therapeutic. 2001;6(6):540-566.
- Matute-Blanch C, Montalban X, Comabella M. Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. Handbook of clinical neurology. 2017;146:67-84.
- Albertsdottir A, Sigurdardottir AK, Thorleifsdottir B. [Prevalence of Poor Sleep Quality and Sleep Disturbances in Icelanders with Multiple Sclerosis]. Laeknabladid. 2019;105(9):379-384.
- Cederberg KLJ, Jeng B, Sasaki JE, Braley TJ, Walters AS, Motl RW. Restless legs syndrome and health-related quality of life in adults with multiple sclerosis. Journal of sleep research. 2019:e12880.
- Lebrato Hernandez L, Prieto Leon M, Cerda Fuentes NA, Ucles Sanchez AJ, Casado Chocan JL, Diaz Sanchez M. Restless legs syndrome in patients with multiple sclerosis: evaluation of risk factors and clinical impact. Neurologia (Barcelona, Spain). 2019.
- Giannaki CD, Aristotelous P, Stefanakis M, et al. Restless legs syndrome in Multiple Sclerosis patients: a contributing factor for fatigue, impaired functional capacity, and diminished health-related quality of life. Neurological research. 2018;40(7):586-592.
- Wang H, Wang K, Xu W, et al. Cerebrospinal fluid alpha-synuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during replase. Journal of neurochemistry. 2012;122(1):19-23.
